Use of Alfuzosin in Stone Treatment With ESWL
Launched by SINGAPORE GENERAL HOSPITAL · Oct 13, 2006
Trial Information
Current as of June 14, 2025
Withdrawn
Keywords
ClinConnect Summary
Urinary tract stones may form in the kidneys or along the ureteric tracts and when left untreated, may result in complications such as pain, bleeding, infection and obstruction. ESWL (extra-corporeal shock wave lithotripsy) has been shown to be an effective and safe method of treatment for kidney and ureteric stones in-situ. In our centre, ESWL is done on an outpatient basis with oral pain killers in the weeks following treatment. Patients are also instructed to increase their fluid intake during this period to expedite the clearance of stone fragments. Alpha1-adrenergic blockers have been ...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All adult patients referred to our centre for ESWL treatment of renal or ureteric stones who give their informed consent.
- Exclusion Criteria:
- • Documented allergy or severe side effects to opioids/ NSAIDs/ Alfuzosin Severe hydronephrosis (on ultrasound or IVU) Radiolucent stones Urinary tract infections Previous pyeloureteral surgery Lower pole stones DJ stents in situ for stones Known renal/hepatic impairment or coagulopathy Pregnant Severe skeletal disease
About Singapore General Hospital
Singapore General Hospital (SGH) is a leading academic medical center in Singapore, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SGH plays a pivotal role in conducting cutting-edge studies that aim to improve patient outcomes and enhance medical knowledge across various specialties. With a strong focus on collaboration and multidisciplinary approaches, SGH leverages its extensive resources and expertise to facilitate rigorous clinical trials, ensuring the highest standards of safety and efficacy in the development of new treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Singapore, , Singapore
Patients applied
Trial Officials
Tsung Wen Chong, MBBS, FRCS
Principal Investigator
SGH Urology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials